
## Jens Schittenhelm

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6782938/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The prognostic role of the immunohistochemical expression of S100 in meningiomas. Journal of Cancer Research and Clinical Oncology, 2023, 149, 2975-2985.	2.5	2
2	<i>PAX6</i> is frequently expressed in ependymal tumours and associated with prognostic relevant subgroups. Journal of Clinical Pathology, 2022, 75, 759-765.	2.0	4
3	Transition of a vestibular schwannoma to a malignant peripheral nerve sheath tumor with loss of H3K27 trimethylation after radiosurgery—a case report and review of the literature. Neurosurgical Review, 2022, 45, 915-922.	2.4	6
4	The immunohistochemical expression of SSTR2A is an independent prognostic factor in meningioma. Neurosurgical Review, 2022, 45, 2671-2679.	2.4	9
5	Frequent FGFR1 hotspot alterations in driver-unknown low-grade glioma and mixed neuronal-glial tumors. Journal of Cancer Research and Clinical Oncology, 2022, 148, 857-866.	2.5	7
6	Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. Acta Neuropathologica Communications, 2022, 10, 5.	5.2	12
7	Patientâ€individual phenotypes of glioblastoma stem cells are conserved in culture and associate with radioresistance, brain infiltration and patient prognosis. International Journal of Cancer, 2022, 150, 1722-1733.	5.1	8
8	GLINT: GlucoCEST in neoplastic tumors at 3ÂT—clinical results of GlucoCEST in gliomas. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2022, 35, 77-85.	2.0	6
9	Complete and Incomplete Resection for Progressive Glioblastoma Prolongs Post-Progression Survival. Frontiers in Oncology, 2022, 12, 755430.	2.8	8
10	Surgical Management of Pre-Chiasmatic Intraorbital Optic Nerve Gliomas in Children after Loss of Visual Function—Resection from Bulbus to Chiasm. Children, 2022, 9, 459.	1.5	0
11	The Current Role of Peptide Receptor Radionuclide Therapy in Meningiomas. Journal of Clinical Medicine, 2022, 11, 2364.	2.4	6
12	The role of Simpson grading in meningiomas after integration of the updated WHO classification and adjuvant radiotherapy. Neurosurgical Review, 2021, 44, 2329-2336.	2.4	18
13	Macrophage and Lymphocyte Infiltration Is Associated with Volumetric Tumor Size but Not with Volumetric Growth in the TA1/4 bingen Schwannoma Cohort. Cancers, 2021, 13, 466.	3.7	9
14	Dynamic Susceptibility Perfusion Imaging for Differentiating Progressive Disease from Pseudoprogression in Diffuse Glioma Molecular Subtypes. Journal of Clinical Medicine, 2021, 10, 598.	2.4	2
15	COX2 expression is associated with preoperative tumor volume but not with volumetric tumor growth in vestibular schwannoma. Neurological Research and Practice, 2021, 3, 11.	2.0	4
16	TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma. Acta Neuropathologica, 2021, 141, 959-970.	7.7	16
17	Differences in the expression of SSTR1–5 in meningiomas and its therapeutic potential. Neurosurgical Review, 2021, , 1.	2.4	12
18	Formalin Fixation as Tissue Preprocessing for Multimodal Optical Spectroscopy Using the Example of Human Brain Tumour Cross Sections. Journal of Spectroscopy, 2021, 2021, 1-14.	1.3	9

#	Article	IF	CITATIONS
19	Loss of H3K27me3 in meningiomas. Neuro-Oncology, 2021, 23, 1282-1291.	1.2	45
20	Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma. Cancers, 2021, 13, 2400.	3.7	28
21	Glioma-Specific Diffusion Signature in Diffusion Kurtosis Imaging. Journal of Clinical Medicine, 2021, 10, 2325.	2.4	6
22	γH2AX foci assay in glioblastoma: Surgical specimen versus corresponding stem cell culture. Radiotherapy and Oncology, 2021, 159, 119-125.	0.6	1
23	Molecular characterisation of sporadic endolymphatic sac tumours and comparison to von Hippel–Lindau diseaseâ€related tumours. Neuropathology and Applied Neurobiology, 2021, 47, 756-767.	3.2	2
24	Brain Invasion in Meningioma—A Prognostic Potential Worth Exploring. Cancers, 2021, 13, 3259.	3.7	18
25	ADC-Based Stratification of Molecular Glioma Subtypes Using High b-Value Diffusion-Weighted Imaging. Journal of Clinical Medicine, 2021, 10, 3451.	2.4	7
26	The molecular hallmarks of primary and secondary vitreoretinal lymphoma. Blood Advances, 2021, , .	5.2	16
27	Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B. Nature Communications, 2021, 12, 5530.	12.8	24
28	Fatal late-onset CAR T-cell–mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma. Blood Advances, 2021, 5, 3789-3793.	5.2	10
29	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	12.8	237
30	H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort. Neuro-Oncology, 2021, 23, 1273-1281.	1.2	34
31	Genetic and epigenetic characterization of posterior pituitary tumors. Acta Neuropathologica, 2021, 142, 1025-1043.	7.7	7
32	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. Journal of Clinical Oncology, 2021, 39, 3839-3852.	1.6	93
33	FGFR3 overexpression is a useful detection tool for FGFR3 fusions and sequence variations in glioma. Neuro-Oncology Practice, 2021, 8, 209-221.	1.6	7
34	Increased proliferation is associated with CNS invasion in meningiomas. Journal of Neuro-Oncology, 2021, 155, 247-254.	2.9	6
35	A Continuous Correlation Between Residual Tumor Volume and Survival Recommends Maximal Safe Resection in Glioblastoma Patients: A Nomogram for Clinical Decision Making and Reference for Non-Randomized Trials. Frontiers in Oncology, 2021, 11, 748691.	2.8	6
36	Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations. Acta Neuropathologica, 2020, 139, 243-257.	7.7	50

#	Article	IF	CITATIONS
37	Diffuse glioneuronal tumour with oligodendrogliomaâ€like features and nuclear clusters (DGONC) – a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14. Neuropathology and Applied Neurobiology, 2020, 46, 422-430.	3.2	51
38	CNS Invasion in Meningioma—How the Intraoperative Assessment Can Improve the Prognostic Evaluation of Tumor Recurrence. Cancers, 2020, 12, 3620.	3.7	12
39	Infratentorial IDH-mutant astrocytoma is a distinct subtype. Acta Neuropathologica, 2020, 140, 569-581.	7.7	45
40	Association of dynamic susceptibility magnetic resonance imaging at initial tumor diagnosis with the prognosis of different molecular glioma subtypes. Neurological Sciences, 2020, 41, 3625-3632.	1.9	4
41	Papillary tumor of the pineal region: a single-center experience. Neuro-Oncology Practice, 2020, 7, 384-390.	1.6	1
42	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discovery, 2020, 10, 942-963.	9.4	157
43	Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. Journal of Clinical Investigation, 2020, 130, 2488-2495.	8.2	23
44	Integrative assessment of brain and bone invasion in meningioma patients. Radiation Oncology, 2019, 14, 132.	2.7	14
45	COX2 expression is associated with proliferation and tumor extension in vestibular schwannoma but is not influenced by acetylsalicylic acid intake. Acta Neuropathologica Communications, 2019, 7, 105.	5.2	17
46	Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. Cancer Immunology Research, 2019, 7, 1910-1927.	3.4	74
47	Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. Acta Neuropathologica Communications, 2019, 7, 163.	5.2	37
48	Diffusion kurtosis imaging histogram parameter metrics predicting survival in integrated molecular subtypes of diffuse glioma: An observational cohort study. European Journal of Radiology, 2019, 112, 144-152.	2.6	17
49	Oncogenic KRAS hotspot mutations are rare in IDHâ€mutant gliomas. Brain Pathology, 2019, 29, 321-324.	4.1	4
50	GENE-13. PEDIATRIC MENINGIOMAS ARE CHARACTERIZED BY DISTINCT METHYLATION PROFILES DIFFERENT FROM ADULT MENINGIOMAS. Neuro-Oncology, 2019, 21, ii83-ii84.	1.2	0
51	T1Ïâ€based dynamic glucoseâ€enhanced (DGEÏ) MRI at 3 T: method development and early clinical experience in the human brain. Magnetic Resonance in Medicine, 2019, 82, 1832-1847.	3.0	43
52	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro-Oncology, 2019, 21, 901-910.	1.2	184
53	Oncogenic BRAF Alterations and Their Role in Brain Tumors. Cancers, 2019, 11, 794.	3.7	62
54	High frequency of H3 K27M mutations in adult midline gliomas. Journal of Cancer Research and Clinical Oncology, 2019, 145, 839-850.	2.5	50

#	Article	IF	CITATIONS
55	In Vivo Molecular Profiling of Human Glioma. Clinical Neuroradiology, 2019, 29, 479-491.	1.9	21
56	Glioma grading by dynamic susceptibility contrast perfusion and 11C-methionine positron emission tomography using different regions of interest. Neuroradiology, 2018, 60, 381-389.	2.2	12
57	Contrast enhancement predicting survival in integrated molecular subtypes of diffuse glioma: an observational cohort study. Journal of Neuro-Oncology, 2018, 139, 373-381.	2.9	14
58	Immunohistochemical comparative analysis of GFAP, MAP – 2, NOGO – A, OLIG – 2 and WT – 1 expression in WHO 2016 classified neuroepithelial tumours and their prognostic value. Pathology Research and Practice, 2018, 214, 15-24.	on 2.3	14
59	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
60	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathologica, 2018, 136, 273-291.	7.7	190
61	<i>CASP9</i> germline mutation in a family with multiple brain tumors. Brain Pathology, 2018, 28, 94-102.	4.1	11
62	Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion. Clinical Neuroradiology, 2018, 28, 421-428.	1.9	52
63	Effect of Perfusion on Diffusion Kurtosis Imaging Estimates for In Vivo Assessment of Integrated 2016 WHO Glioma Grades. Clinical Neuroradiology, 2018, 28, 481-491.	1.9	10
64	Low FoxG1 and high Oligâ€2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)â€mutant gliomas. Neuropathology and Applied Neurobiology, 2018, 44, 207-223.	3.2	10
65	In vivo assessment of tumor heterogeneity in WHO 2016 glioma grades using diffusion kurtosis imaging: Diagnostic performance and improvement of feasibility in routine clinical practice. Journal of Neuroradiology, 2018, 45, 32-40.	1.1	33
66	Characterization of Diffuse Gliomas With Histone H3-G34 Mutation by MRI and Dynamic 18F-FET PET. Clinical Nuclear Medicine, 2018, 43, 895-898.	1.3	33
67	High Expression of Somatostatin Receptors 2A, 3, and 5 in Corticotroph Pituitary Adenoma. International Journal of Endocrinology, 2018, 2018, 1-12.	1.5	15
68	MNGI-11. LONGITUDINAL GENOMIC ANALYSIS OF SPORADIC MENINGIOMAS WITH MULTIPLE RECURRENCES. Neuro-Oncology, 2018, 20, vi150-vi150.	1.2	0
69	Transsphenoidal Removal of Recurrent Osteoid Osteoma of Clivus. World Neurosurgery, 2018, 120, 506-508.	1.3	3
70	Tissue microarrays – translational biomarker research in the fast lane. Expert Review of Molecular Diagnostics, 2018, 18, 833-835.	3.1	13
71	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. Acta Neuropathologica, 2018, 136, 239-253.	7.7	118
72	NFM-11. PEDIATRIC MENINGIOMAS ARE MOLECULARLY DISTINCT FROM ADULT COUNTERPARTS. Neuro-Oncology, 2018, 20, i144-i145.	1.2	1

#	Article	IF	CITATIONS
73	The Cellular Retinoic Acid Binding Protein 2 Promotes Survival of Malignant Peripheral Nerve Sheath Tumor Cells. American Journal of Pathology, 2017, 187, 1623-1632.	3.8	17
74	Recent advances in subtyping tumors of the central nervous system using molecular data. Expert Review of Molecular Diagnostics, 2017, 17, 83-94.	3.1	10
75	Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma. Oncologist, 2017, 22, 570-575.	3.7	23
76	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncology, The, 2017, 18, 682-694.	10.7	586
77	Prognostic parameters and outcome after re-irradiation for progressive glioblastoma. Acta Neurologica Scandinavica, 2017, 136, 239-245.	2.1	14
78	Implications of Vestibular Schwannoma Consistency: Analysis of 140 Cases Regarding Radiologic and Clinical Features. World Neurosurgery, 2017, 99, 159-163.	1.3	13
79	Histogram analysis of diffusion kurtosis imaging estimates for in vivo assessment of 2016 WHO glioma grades: A cross-sectional observational study. European Journal of Radiology, 2017, 95, 202-211.	2.6	26
80	The Prognostic Impact of Ventricular Opening in Glioblastoma Surgery: A Retrospective Single Center Analysis. World Neurosurgery, 2017, 106, 615-624.	1.3	19
81	Risk Factors of Preoperative and Early Postoperative Seizures in Patients with Meningioma: A Retrospective Single-Center Cohort Study. World Neurosurgery, 2017, 97, 538-546.	1.3	37
82	In vivo molecular profiling of human glioma using diffusion kurtosis imaging. Journal of Neuro-Oncology, 2017, 131, 93-101.	2.9	56
83	MR spectroscopy for in vivo assessment of the oncometabolite 2â€hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T. Journal of Magnetic Resonance Imaging, 2016, 44, 823-833.	3.4	36
84	Endothelial cellâ€derived angiopoietinâ€2 is a therapeutic target in treatmentâ€naive and bevacizumabâ€resistant glioblastoma. EMBO Molecular Medicine, 2016, 8, 39-57.	6.9	140
85	EBV-negative aggressive B-cell lymphomas of donor origin after allogeneic hematopoietic stem cell transplantation: a report of three cases. Leukemia and Lymphoma, 2016, 57, 2603-2611.	1.3	7
86	Frequency of BRAF V600E mutations in 969 central nervous system neoplasms. Diagnostic Pathology, 2016, 11, 55.	2.0	95
87	HG-68COMBINED ALTERATIONS IN MAPK PATHWAY GENES, CDKN2A/B AND ATRX CHARACTERIZE ANAPLASTIC PILOCYTIC ASTROCYTOMA. Neuro-Oncology, 2016, 18, iii63.2-iii63.	1.2	0
88	Brain invasion in otherwise benign meningiomas does not predict tumor recurrence. Acta Neuropathologica, 2016, 132, 479-481.	7.7	54
89	ATRX immunostaining predicts IDH and H3F3A status in gliomas. Acta Neuropathologica Communications, 2016, 4, 60.	5.2	100
90	Deubiquitylating enzyme USP9x regulates radiosensitivity in glioblastoma cells by Mcl-1-dependent and -independent mechanisms. Cell Death and Disease, 2016, 7, e2039-e2039.	6.3	30

#	Article	IF	CITATIONS
91	Methylation-based classification of benign and malignant peripheral nerve sheath tumors. Acta Neuropathologica, 2016, 131, 877-887.	7.7	151
92	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	28.9	702
93	TERT Promoter Mutations and Risk of Recurrence in Meningioma. Journal of the National Cancer Institute, 2016, 108, djv377.	6.3	283
94	Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathologica, 2016, 131, 137-146.	7.7	162
95	Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549–BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification. Journal of Cancer Research and Clinical Oncology, 2016, 142, 89-100.	2.5	46
96	The role of integrins in primary and secondary brain tumors. Histology and Histopathology, 2016, 31, 1069-78.	0.7	8
97	Predictors of preoperative and early postoperative seizures in patients with intraâ€axial primary and metastatic brain tumors: A retrospective observational single center study. Annals of Neurology, 2015, 78, 917-928.	5.3	60
98	CNS metastases in breast cancer patients: prognostic implications of tumor subtype. Medical Oncology, 2015, 32, 400.	2.5	22
99	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathologica, 2015, 130, 407-417.	7.7	237
100	Tumour necrosis factor receptor superfamily member 9 ( <scp>TNFRSF</scp> 9) is upâ€regulated in reactive astrocytes in human gliomas. Neuropathology and Applied Neurobiology, 2015, 41, e56-67.	3.2	7
101	<scp>P</scp> aired box gene 8 ( <scp>PAX8</scp> ) expression is associated with sonic hedgehog ( <scp>SHH</scp> )/wingless int ( <scp>WNT</scp> ) subtypes, desmoplastic histology and patient survival in human medulloblastomas. Neuropathology and Applied Neurobiology, 2015, 41, 165-179.	3.2	4
102	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated―diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathologica, 2015, 129, 133-146.	7.7	378
103	Prognostic Value of Blood Flow Measurements Using Arterial Spin Labeling in Gliomas. PLoS ONE, 2014, 9, e99616.	2.5	31
104	Correlative assessment of tumor microcirculation using contrastâ€enhanced perfusion MRI and intravoxel incoherent motion diffusionâ€weighted MRI: is there a link between them?. NMR in Biomedicine, 2014, 27, 1184-1191.	2.8	50
105	Prognostic value of blood flow estimated by arterial spin labeling and dynamic susceptibility contrast-enhanced MR imaging in high-grade gliomas. Journal of Neuro-Oncology, 2014, 120, 557-566.	2.9	24
106	The embryonic stem cell factor UTF1 serves as a reliable diagnostic marker for germinomas. Pathology, 2014, 46, 225-229.	0.6	8
107	Risk factors and survival outcome in cerebral metastatic breast cancer. Medical Oncology, 2014, 31, 862.	2.5	2
108	Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms. Acta Neuropathologica, 2014, 127, 565-572.	7.7	41

#	Article	IF	CITATIONS
109	<scp><i>BRAF</i></scp> â€Mutated Pleomorphic Xanthoastrocytoma is Associated with Temporal Location, Reticulin Fiber Deposition and <scp>CD</scp> 34 Expression. Brain Pathology, 2014, 24, 221-229.	4.1	72
110	WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma. Journal of Clinical Pathology, 2014, 67, 556-561.	2.0	25
111	αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer. Clinical and Experimental Metastasis, 2014, 31, 841-851.	3.3	51
112	A novel mutation in LRSAM1 causes axonal Charcot-Marie-Tooth disease with dominant inheritance. BMC Neurology, 2014, 14, 118.	1.8	20
113	Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathologica, 2014, 128, 551-559.	7.7	268
114	Intravoxel incoherent motion diffusion-weighted MR imaging of gliomas: feasibility of the method and initial results. Neuroradiology, 2013, 55, 1189-1196.	2.2	91
115	CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary. Journal of Cancer Research and Clinical Oncology, 2013, 139, 551-556.	2.5	25
116	Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathologica, 2013, 125, 891-900.	7.7	177
117	VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation. Acta Neuropathologica, 2013, 125, 911-912.	7.7	28
118	Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathologica, 2013, 125, 651-658.	7.7	324
119	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathologica, 2013, 126, 907-915.	7.7	254
120	Invasion patterns in brain metastases of solid cancers. Neuro-Oncology, 2013, 15, 1664-1672.	1.2	191
121	Comparison of Three Different MR Perfusion Techniques and MR Spectroscopy for Multiparametric Assessment in Distinguishing Recurrent High-Grade Gliomas from Stable Disease. Academic Radiology, 2013, 20, 1557-1565.	2.5	93
122	AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. Acta Neuropathologica, 2013, 126, 757-762.	7.7	88
123	Receptor change-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1909-1916.	2.5	15
124	Longitudinal Expression Analysis of αv Integrins in Human Gliomas Reveals Upregulation of Integrin αvβ3 as a Negative Prognostic Factor. Journal of Neuropathology and Experimental Neurology, 2013, 72, 194-210.	1.7	46
125	Prognostic relevance of global histone 3 lysine 9 acetylation in ependymal tumors. Journal of Neurosurgery, 2013, 119, 1424-1431.	1.6	9
126	Differential Expression of the Tumor Suppressor A-Kinase Anchor Protein 12 in Human Diffuse and Pilocytic Astrocytomas Is Regulated by Promoter Methylation. Journal of Neuropathology and Experimental Neurology, 2013, 72, 933-941.	1.7	11

#	Article	IF	CITATIONS
127	Osteonectin Expression in Surrounding Stroma of Craniopharyngiomas. International Journal of Surgical Pathology, 2013, 21, 591-598.	0.8	10
128	Evaluation of invasion patterns and their correlation with integrin alphavbeta expression in brain metastases of solid cancers Journal of Clinical Oncology, 2013, 31, 2059-2059.	1.6	1
129	Comparing the expression of integrins αvβ3, αvβ5, αvβ6, αvβ8, fibronectin and fibrinogen in human brain metastases and their corresponding primary tumors. International Journal of Clinical and Experimental Pathology, 2013, 6, 2719-32.	0.5	29
130	Notch receptors in human choroid plexus tumors. Histology and Histopathology, 2013, 28, 1055-63.	0.7	11
131	Diagnostic Value of EAAT-1 and Kir7.1 for Distinguishing Endolymphatic Sac Tumors From Choroid Plexus Tumors. American Journal of Clinical Pathology, 2012, 138, 85-89.	0.7	24
132	Management of Holocord Pilocytic Astrocytomas in Children and Adolescents: An Update. Pediatric Neurosurgery, 2012, 48, 133-140.	0.7	12
133	Hybrid Neurofibroma/Schwannoma is Overrepresented Among Schwannomatosis and Neurofibromatosis Patients. American Journal of Surgical Pathology, 2012, 36, 702-709.	3.7	109
134	Activated leukocyte cell adhesion molecule is expressed in neuroepithelial neoplasms and decreases with tumor malignancy, matrix metalloproteinase 2 expression, and absence of IDH1R132H mutation. Human Pathology, 2012, 43, 1289-1299.	2.0	6
135	Pituicytoma in a patient with Cushing's disease: case report and review of the literature. Pituitary, 2012, 15, 10-16.	2.9	32
136	Intraspinal Oncocytic Adrenocortical Adenoma: Diagnosis. , 2012, , 77-79.		0
137	Paediatric clear cell meningioma with multiple distant recurrences after presumed intra-operative cell spread. Child's Nervous System, 2012, 28, 925-931.	1.1	9
138	The "go or grow―potential of gliomas is linked to the neuropeptide processing enzyme carboxypeptidase E and mediated by metabolic stress. Acta Neuropathologica, 2012, 124, 83-97.	7.7	66
139	Increased [11C]PIB-PET levels in inclusion body myositis are indicative of amyloid  deposition. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1060-1062.	1.9	22
140	Atypical teratoid/rhabdoid tumors may show morphological and immunohistochemical features seen in choroid plexus tumors. Neuropathology, 2011, 31, 461-467.	1.2	25
141	CD133 expression is associated with small round blue cell tumour morphology in human central nervous system neoplasms. Histopathology, 2011, 58, 739-749.	2.9	5
142	Histone Acetylation Patterns of Typical and Atypical Pituitary Adenomas Indicate Epigenetic Shift of these Tumours. Journal of Neuroendocrinology, 2011, 23, 525-530.	2.6	15
143	Spinal metastasis of endometrial stromal sarcoma: Clinicopathological features and management. Surgical Oncology, 2011, 20, e78-e83.	1.6	8
144	Parenchymal accumulation of CD163+ macrophages/microglia in multiple sclerosis brains. Journal of Neuroimmunology, 2011, 237, 73-79.	2.3	114

#	Article	IF	CITATIONS
145	Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathologica, 2011, 121, 241-252.	7.7	124
146	Confirmation of R132H mutation of isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma. Acta Neuropathologica, 2011, 122, 651-652.	7.7	13
147	Slowly progressive Parkinson syndrome due to thalamic butterfly astrocytoma. Neurology, 2011, 77, 404-405.	1.1	6
148	Hypoxia-Inducible Factor-1α–Dependent Protection from Intestinal Ischemia/Reperfusion Injury Involves Ecto-5′-Nucleotidase (CD73) and the A2B Adenosine Receptor. Journal of Immunology, 2011, 186, 4367-4374.	0.8	120
149	De novo expression of the hemoglobin scavenger receptor CD163 by activated microglia is not associated with hemorrhages in human brain lesions. Histology and Histopathology, 2011, 26, 1007-17.	0.7	32
150	Erythropoietin receptor expression in normal and neoplastic choroid plexus. , 2011, 30, 33-40.		2
151	Application of Mutant IDH1 Antibody to Differentiate Diffuse Glioma From Nonneoplastic Central Nervous System Lesions and Therapy-induced Changes. American Journal of Surgical Pathology, 2010, 34, 1199-1204.	3.7	108
152	Secreted protein, acidic and rich in cysteine (SPARC) expression in astrocytic tumour cells negatively correlates with proliferation, while vascular SPARC expression is associated with patient survival. Neuropathology and Applied Neurobiology, 2010, 36, 183-197.	3.2	16
153	Balancing the Shortcomings of Microscope and Endoscope: Endoscope-Assisted Technique in Microsurgical Removal of Recurrent Epidermoid Cysts in the Posterior Fossa. Minimally Invasive Neurosurgery, 2010, 53, 218-222.	0.9	28
154	WT1 expression in normal and neoplastic cranial and peripheral nerves is independent of grade of malignancy. Cancer Biomarkers, 2010, 7, 73-77.	1.7	17
155	Glioblastoma with granular cell astrocytoma features: a case report and literature review. , 2010, 29, 323-329.		19
156	Cerebral low-grade lymphoma and light chain deposition disease: exceedingly high IgG levels in the cerebrospinal fluid as a diagnostic clue. , 2010, 29, 378-383.		12
157	Expression of EAAT-1 distinguishes choroid plexus tumors from normal and reactive choroid plexus epithelium. Acta Neuropathologica, 2009, 117, 667-675.	7.7	24
158	Symptomatic Intraspinal Oncocytic Adrenocortical Adenoma. Endocrine Pathology, 2009, 20, 73-77.	9.0	34
159	Diagnostic value of WT1 in neuroepithelial tumours. Neuropathology and Applied Neurobiology, 2009, 35, 69-81.	3.2	24
160	Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival. Modern Pathology, 2009, 22, 1600-1611.	5.5	24
161	Aryl hydrocarbon receptor inhibition downregulates the TGF-β/Smad pathway in human glioblastoma cells. Oncogene, 2009, 28, 2593-2605.	5.9	106
162	Holocord pilocytic astrocytoma—Case report and review of the literature. Clinical Neurology and Neurosurgery, 2009, 111, 203-207.	1.4	21

3

#	Article	IF	CITATIONS
163	Rathke's cleft cyst rupture as potential initial event of a secondary perifocal lymphocytic hypophysitis: proposal of an unusual pathogenetic event and review of the literature. Neurosurgical Review, 2008, 31, 157-163.	2.4	31
164	Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. Acta Neuropathologica, 2008, 115, 249-259.	7.7	68
165	WT1 Expression Distinguishes Astrocytic Tumor Cells from Normal and Reactive Astrocytes. Brain Pathology, 2008, 18, 344-353.	4.1	28
166	The clinico-surgico-pathological spectrum of myxopapillary ependymomas — report of four unusal cases and review of the literature. , 2008, 27, 21-28.		18
167	Primary anaplastic ganglioglioma with a small-cell glioblastoma component. , 2008, 27, 91-95.		15
168	Gliosarcoma with chondroid and osseous differentiation. Neuropathology, 2007, 27, 90-94.	1.2	18
169	Multifocal dysembryoplastic neuroepithelial tumor with signs of atypia after regrowth. Neuropathology, 2007, 27, 383-389.	1.2	24
170	The astrocytic response towards invasive meningiomas. Neuropathology and Applied Neurobiology, 2007, 33, 163-168.	3.2	23
171	Patterns of SPARC expression and basement membrane intactness at the tumour?brain border of invasive meningiomas. Neuropathology and Applied Neurobiology, 2006, 32, 525-531.	3.2	29

172 Molecular Advances in Glioblastoma Neuropathology. , 0, , .